Evidence map›Paper›PMID 40745254›Full record

ArticleScientific reports2025

Novel anti-VEGF scFv antibodies with superior in vitro and in vivo activities.

Gulcin Cakan-Akdogan, Ozlem Erez, Ceren Ozer, Ebru Onal, Olcay Mert, Seyda Gullu, Merve Arslan, Mehmet Ender Avci, Mehmet Inan, Sibel Kalyoncu

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Gulcin Cakan-AkdoganIzmir Biomedicine and Genome Center, 35340, Izmir, Türkiye. gulcin.cakan@ibg.edu.tr.
Ozlem ErezIzmir Biomedicine and Genome Center, 35340, Izmir, Türkiye.
Ceren OzerIzmir Biomedicine and Genome Center, 35340, Izmir, Türkiye.
Ebru OnalIzmir Biomedicine and Genome Center, 35340, Izmir, Türkiye.
Olcay MertIzmir Biomedicine and Genome Center, 35340, Izmir, Türkiye.
Seyda GulluIzmir Biomedicine and Genome Center, 35340, Izmir, Türkiye.
Merve ArslanIzmir Biomedicine and Genome Center, 35340, Izmir, Türkiye.
Mehmet Ender AvciIzmir Biomedicine and Genome Center, 35340, Izmir, Türkiye.
Mehmet InanIzmir Biomedicine and Genome Center, 35340, Izmir, Türkiye.
Sibel KalyoncuIzmir Biomedicine and Genome Center, 35340, Izmir, Türkiye. sibel.kalyoncu@ibg.edu.tr.

Funding

European Commission RareBoost Project #952346Türkiye Bilimsel ve Teknolojik Araştırma Kurumu 119Z161VSY Biotechnology IBG002
6 · The paper itself

Abstract

Vascular Endothelial Growth Factor (VEGF) plays important roles in the pathogenesis of age-related macular degeneration (AMD), the most common cause of vision loss in the elderly. Intravitreal anti-VEGF injection is the gold standard for AMD treatment. Here three novel anti-VEGF single chain variable fragments (scFvs) produced in Pichia pastoris system are reported. First, an scFv was designed based on the variable chain sequence of ranibizumab, then rational mutations were introduced to find the best variant(s). Mutagenesis of two residues that normally reside at the Fab V

Indexed as

Angiogenesis InhibitorsSingle-Chain AntibodiesVascular Endothelial Growth Factor AAnimalsBevacizumabCell ProliferationHumansHuman Umbilical Vein Endothelial CellsMacular DegenerationPichiaRanibizumabZebrafishAngiogenesis InhibitorsBevacizumabRanibizumabSingle-Chain AntibodiesVascular Endothelial Growth Factor AAngiogenesisHUVECSingle chain variable fragmentVEGFZebrafish

Identifiers

PMID40745254
PMCPMC12314078

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.